Metformin in cancer prevention and therapy

Annals of Translational Medicine

Volumn 2, Issue 6, 2014, Pages

  Kasznicki, Jacek ^a   Sliwinska, Agnieszka ^a   Drzewoski, Józef ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cancer; Clinical evidence; Metformin; Molecular action

Indexed keywords

EID: 85015471827     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.3978/j.issn.2305-5839.2014.06.01     Document Type: Review

References (63)

1. Smith U, Gale EM. Cancer and diabetes: are we ready for prime time? Diabetologia 2010;53:1541-4.
2. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-85.
3. Bonovas S, Filloussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004;47:1071-8.
4. Barone BB, Yeh HC, Snyder CF, et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care 2010:33:931-9.
5. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development and outcomes of cancer. Nat Clin Pract Oncol 2005;2:48-53.
6. Smith U, Gale EM. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52:1699-708.
7. Azar M, Lyons TJ. Diabetes, insulin treatment and cancer: what is the evidence? F1000 Med Rep 2010;2. pii: 4.
8. Drzewoski J, Drozdowska A, Sliwinska A. Do we have enough data to confirm the link between antidiabetic drug use and cancer development? Pol Arch Med Wewn 2011;121:81-7.
9. Schiel R, Müller UA, Braun A, et al. Risk of malignancies in patients with insulin-treated diabetes mellitus: results of a population-based trial with 10-year follow-up (JEVIN). Eur J Med Res 2005;10:339-44.
10. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use SU or insulin. Diabetes Care 2006;29:254-8.
11. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-44.
12. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007;13:433-42.
13. Memmott RM, Mercado JR, Maier CR, et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila) 2010;3:1066-76.
14. Drzewoski J, Drozdowska A, Sliwinska A. Do we have enough data to confirm the link between antidiabetic drug use and cancer development? Pol Arch Med Wewn 2011;121:81-7.
15. LeRoith D, Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med 1995;122:54-9.
16. Memmott RM, Mercado JR, Maier CR, et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila) 2010;3:1066-76.
17. Yoshida S, Hong S, Suzuki T, et al. Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway. J Biol Chem 2011;286:32651-60.
18. Dowling RJ, Zakikhani M, Fantus IG, et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67:10804-12.
19. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-73.
20. Mohammed A, Janakiram NB, Brewer M, et al. Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. Transl Oncol 2013;6:649-59.
21. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008;30:214-26.
22. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 2004;101:3329-35.
23. Algire C, Amrein L, Bazile M, et al. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 2011;30:1174-82.
24. Shackelford DB, Abt E, Gerken L, et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013;23:143-58.
25. Hadad SM, Hardie DG, Appleyard V, et al. Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol 2013. [Epub ahead of print].
26. Ben Sahra I, Laurent K, Giuliano S, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010;70:2465-75.
27. Zhuang Y, Miskimins WK. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 2008;3:18.
28. Malki A, Youssef A. Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol Res 2011;19:275-85.
29. Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, et al. In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol 2011;668:373-82.
30. Nelson LE, Valentine RJ, Cacicedo JM, et al. A novel inverse relationship between metformin-triggered AMPK-SIRT1 signaling and p53 protein abundance in high glucose-exposed HepG2 cells. Am J Physiol Cell Physiol 2012;303:C4-13.
31. Cerezo M, Tichet M, Abbe P, et al. Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol Cancer Ther 2013;12:1605-15.
32. Yi G, He Z, Zhou X, et al. Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway. Int J Oncol 2013;43:1503-10.
33. Kalender A, Selvaraj A, Kim SY, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010;11:390-401.
34. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 2009;8:88-96.
35. Chung J, Kuo CJ, Crabtree GR, et al. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992;69:1227-36.
36. Ben Sahra I, Regazzetti C, Robert G, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 2011;71:4366-72.
37. United Kingdom Diabetes study group, United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310:83-8.
38. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol 2012;29:1314-27.
39. Quinn BJ, Kitagawa H, Memmott RM, et al. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 2013;24:469-80.
40. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5.
41. Currie CJ, Poole CD, Jenkins-Jones S, et al. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012;35:299-304.
42. Franciosi M, Lucisano G, Lapice E, et al. Metformin Therapy and Risk of Cancer in Patients with T2DM: Systematic Review. PLoS One 2013;8:e71583.
43. Soranna D, Scotti L, Zambon A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012;17:813-22.
44. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 2012;35:119-24.
45. Chlebowski RT, McTiernan A, Wactawski-Wende J, et al. Diabetes, Metformin, and Breast Cancer in Postmenopausal Women. J Clin Oncol 2012;30:2844-52.
46. Home PD, Kahn SE, Jones NP, et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010;53:1838-45.
47. Zhang ZJ, Zheng Z, Kan H, et al. Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With T2DM. A meta-analysis. Diabetes Care 2011;34:2323-8.
48. Noto H, Goto A, Tsujimoto T, et al. Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis. PLoS One 2012;7:e33411.
49. Mamtani R, Pfanzelter N, Heynes K, et al. Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or SU. Diabetes Care 2014;37:1910-7.
50. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731.
51. Ioannou GN, Boyko EJ. Metformin and Colorectal Cancer Risk in Diabetic Patients. Diabetes Care 2011;34:2336-7.
52. Quinn BJ, Kitagawa H, Memmott RM, et al. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 2013;24:469-80.
53. Dilman VM, Berstein LM, Yevtushenko TP, et al. Preliminary evidence on metabolic rehabilitation of cancer patients. Arch Geschwulstforsch 1988;58:175-83.
54. Goodwin PJ, Pritchard KI, Ennis M, et al. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 2008;8:501-5.
55. Campagnoli C, Pasanisi P, Abbà C, et al. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin Breast Cancer 2012;12:175-82.
56. Hadad S, Iwamoto T, Jordan L, et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011;128:783-94.
57. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 2010;3:1077-83.
58. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297-302.
59. Margel D, Urbach DR, Lipscombe LL, et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013;31:3069-75.
60. Quinn BJ, Kitagawa H, Memmott RM, et al. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 2013;24:469-80.
61. Nobes JP, Langley SE, Klopper T, et al. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2012;109:1495-502.
62. Rezzónico J, Rezzónico M, Pusiol E, et al. Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Relat Disord 2011;9:69-75.
63. A registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. Available online: www. ClinicalTrials.gov